180 related articles for article (PubMed ID: 30663219)
21. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
[TBL] [Abstract][Full Text] [Related]
22. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
[TBL] [Abstract][Full Text] [Related]
23. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.
Li C; Wang MD; Lu L; Wu H; Yu JJ; Zhang WG; Pawlik TM; Zhang YM; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Xing H; Li ZL; Lau WY; Wu MC; Shen F; Yang T
Hepatol Int; 2019 Nov; 13(6):736-747. PubMed ID: 31486964
[TBL] [Abstract][Full Text] [Related]
24. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Labenz C; Prenosil V; Koch S; Huber Y; Marquardt JU; Schattenberg JM; Galle PR; Weinmann A; Wörns MA
Dig Dis; 2018; 36(1):78-88. PubMed ID: 28675895
[TBL] [Abstract][Full Text] [Related]
25. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
26. Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis.
Chinnaratha MA; Campbell K; Mathias R; McCormick RJ; Woodman RJ; Wigg AJ
J Gastrointest Cancer; 2019 Dec; 50(4):888-893. PubMed ID: 30345486
[TBL] [Abstract][Full Text] [Related]
27. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
29. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
30. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation.
Chen TM; Lin CC; Huang PT; Wen CF
J Gastroenterol Hepatol; 2011 May; 26(5):858-65. PubMed ID: 21251068
[TBL] [Abstract][Full Text] [Related]
31. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma.
Labeur TA; Ten Cate DWG; Bart Takkenberg R; Azahaf H; van Oijen MGH; van Delden OM; de Man RA; van Vugt JLA; IJzermans JNM; Eskens FALM; Klümpen HJ
Acta Oncol; 2018 Nov; 57(11):1467-1474. PubMed ID: 29943624
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
[TBL] [Abstract][Full Text] [Related]
33. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study.
Leal CRG; Magalhães C; Barbosa D; Aquino D; Carvalho B; Balbi E; Pacheco L; Perez R; de Tarso Pinto P; Setubal S
Invest New Drugs; 2018 Oct; 36(5):911-918. PubMed ID: 29948358
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
35. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Ozenne V; Paradis V; Pernot S; Castelnau C; Vullierme MP; Bouattour M; Valla D; Farges O; Degos F
Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1106-10. PubMed ID: 20300004
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
Ziogas DC; Papadatos-Pastos D; Thillai K; Korantzis I; Chowdhury R; Suddle A; O'Grady J; Al-Khadimi G; Allen N; Heaton N; Ross PJ; Sarker D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):48-55. PubMed ID: 27623000
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Hollebecque A; Cattan S; Romano O; Sergent G; Mourad A; Louvet A; Dharancy S; Boleslawski E; Truant S; Pruvot FR; Hebbar M; Ernst O; Mathurin P
Aliment Pharmacol Ther; 2011 Nov; 34(10):1193-201. PubMed ID: 21958438
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
[TBL] [Abstract][Full Text] [Related]
40. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Tseng CH
Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
